Master of Musical Chairs
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OMHE FDA Orphan Drug Designation - FAST TRACK $omhe THIS IS HUGE
https://blogs.fda.gov/fdavoice/index.php/tag/fast-track/
https://en.wikipedia.org/wiki/Fast_track_(FDA)
Market agrees $OMHE
$OMHE red rocket
imagine not having to use a credit card the next time going to applebees imagine paying cash $OMHE lets me do that cause I invested and didn't post nonsense
From $OMHE newest board member Dr. Aliffe LinkedIn .. could this be $OMHE newest partner in Joint Venture?
Rylie’s Sunshine Health Sciences
Dates Employed
Jun 2017 – Present
Employment Duration
7 mos
Location
San Diego, CA & México City, D.F., MEXICO
Early-stage, Ethics-driven, Medical Marijuana, Translational Medicine Start-up, translating Marijuana Folk Medicine into reliable Clinical-Quality Cannabis.
Applying molecular pharmacognosy to yield safe and effective, IP-rich, cannabis-centered products in support of optimal well-being and sustainable longevity.
• Consumer and B2B markets North America (USA, México and Canada), South America and Australia.
• Endocannabinoid Synergy Product Development Pipeline~ Clinical Trials and Consumer Testing.
• Science-driven Branding & Marketing, Regulatory and Intellectual Property Strategies.
• International Academic and Basic Science Research Liaison.
• Ethics-centered Regulatory Lobbying and New Business Development.
• Health Practitioner and Community Education Programs & Resources.
• Mobile Endocannabinoid System Personal Health Consultation Services
Chief Executive Scientist
Company Name
Sophipraxia ~ Praxigen Biomedia
Dates Employed
1995 – Present
Employment Duration
22 yrs
Location
Washington
Praxigen Biomedia is the visionary application of translational sciences and integrative therapeutics in the research and discovery of vital breakthrough remedies and quintessential life enhancement strategies. Our focus is to bridge the gap between scientific theory and clinical practice, between anecdotal experience and objective discovery, to actualize the fullest of human benefit and maximize fiscal success through pristine integrity and unfailing intelligence.
Industry Expertise
• Molecule-to-Market Pipeline Development. Evidence-based Optimization of Active Constituents (e.g., oligosaccharides, cannabinoids, curcuminoids) into reproducible formulations and valid activity claims
• Medicinal Chemistry, Molecular Pharmacognosy and Clinical Pharmacology approaches repurposed for Cannabis spp. to effect discovery of novel phytomedicinal agents
• Health Professional Training~ e.g., Clinical Cannabis & the Endocannabinoid System Immunosenescence, Cancer, Longevity
• Phase I-IV Clinical Trial Strategies, NDA Planning and Management
Focus Areas
• Immunosenescence~ Prevention, Preemption and Palliation of Diseases Associated with Pathological Aging
• Extreme or “Unhealthy” Lifestyle Support, e.g., Elite Military, HIV/AIDS Partner Protection, Smokers, etc.
• Intellectual Property Development, translating research data into marketable product and indications
• Immune Optimization~ Enhancing Human Immunity Against Carcinogenesis and Viral Diseases
• Cannaesthesia~ Human Noometric Effects Monitoring of Psychotropic Natural Medicinals
• Micronutrient formulation to promote stem cell re-activation and intrinsic healing
• Neuroscience~ Natural Products-based Alzheimer's Disease Therapies/Adjuvants
• Sports Medicine~ Optimizing Cognitive Function and Recovery Times
Specialized Functions
• Science-based marketing and promotional health claims strategies
• Regulatory standards compliance, Structure-function product labeling and insert materials guidance
$OMHE Dr. Karyemaitre Aliffe, MD official linkedin page https://www.linkedin.com/in/karyemaliffe/ check out his recent shared topics and articles HARVARD- AND STANFORD-TRAINED, ENTREPRENEURIAL PHYSICIAN~SCIENTIST
Multilingual Biomedical Executive and Engaging Public Speaker with 25+ Years Strategic Visionary Leadership Leveraging Breakthrough Science into Novel Medicinal Agents and Biotechnologies.
FOCUS~
Molecular & Clinical Pharmacognosy
? Clinical Cannabis / Medicinal Marijuana
? Immunomodulation and Anti-Carcinogenesis
? Clinical Trials of Complex Natural Product Medicinals
? Quantitative Assessment of Therapeutic & Psychotropic Effects
? Human Performance Enhancement/Impairment Products Assessment
Integrative Product Pipeline Development and Science-based Marketing Strategies
? Evidence-based Development of Effective, Non-toxic, Medicinal Agents
? Proprietary Practitioner Formulations & Protocol Development
? Health Professional, Self-Care and OTC Market Capture
Translational Medicine and Bioethics
? Compassionate Use and "n-of-1" Trials
? Clinical Cannabis / Medicinal Marijuana
? Psychoneuroimmunology and Longevity
? EXECUTIVE LEADERSHIP & BUSINESS DEVELOPMENT
? Conscientious Professional, Proficient in the Liaison of Sound Science and Successful Commerce, efficiently managing capital, intellectual and personnel resources to meet and exceed projected goals.
? Team-Oriented Executive with Successful Global Experience Building Growth and Profitability by advancing scientific leadership position and competitive expansion into global niche markets, effectively managing regulatory affairs in accord with regional and international guidelines.
? STRATEGIC INNOVATION, DISCOVERY & IMPLEMENTATION
? Visionary Thought Leader, Providing Practicable Concepts to Initiate and Advance Leading-Edge Sciences in accord with accomplishment of corporate objectives.
? Cross-functional Management Expertise, Creating High-Productivity, Cooperative Networking among biomedical, technical and regulatory personnel, and in interface with corporate partners, extramural contractors, fiscal managers and investors.
Good morning what a day so far as liquid as I have ever seen this stock $OWCP big money flowing in still you can tell how coordinated market makers are behaving brokers have large orders to help get filled and make that year end commission .. this is going back to dollar land you cannot deny the accumulation strength ... $OWCP God Bless God Speed
$OHME https://finnewsreview.com/chartists-taking-aim-at-omni-health-inc-omhe-shares/ Chartists Taking Aim at Omni Health Inc. (OMHE) Shares
Financial News Review - 8h ago
Shares of Omni Health Inc. (OMHE) are on watch as the Tenkan Line has moved above the Kijun line, indicating positive momentum for the equity.Chartists Taking Aim at Omni Health Inc. (OMHE) Shares
Financial News Review - 8h ago
Shares of Omni Health Inc. (OMHE) are on watch as the Tenkan Line has moved above the Kijun line, indicating positive momentum for the equity.
$OHME https://finnewsreview.com/chartists-taking-aim-at-omni-health-inc-omhe-shares/ Chartists Taking Aim at Omni Health Inc. (OMHE) Shares
Financial News Review - 8h ago
Shares of Omni Health Inc. (OMHE) are on watch as the Tenkan Line has moved above the Kijun line, indicating positive momentum for the equity.Chartists Taking Aim at Omni Health Inc. (OMHE) Shares
Financial News Review - 8h ago
Shares of Omni Health Inc. (OMHE) are on watch as the Tenkan Line has moved above the Kijun line, indicating positive momentum for the equity.
$OMHE AMAZING CHARTS PETEY THANKS
$OWCP 200sma .66 let's go
$OMHE Omni Health going to be a top medical cannabis play going into 2018
weekly chart tells the story big time move coming no resistance past .03 could go to .10+ in a day $OMHE medical cannabis stock of 2018
Theory based on fact.. you have a large % of O/S as restricted so the remaining 300m in the float as unrestricted shares is closely held by big money you have a 10% holder in MCIG as well obviously there's confidence in HOLDING these shares otherwise you would have seen higher volume days due to dumping .. bottom line impatient retail investors have sold and those sharws have found secure hands with deep pockets this is going alot higher life changing stock here $OMHE
Amen $OWCP
Shows what you know lmfao in states where legal medical marijuana is legal no FDA approval Is needed unless prescribed by a doctor so they can sell their pain meds derived from cannabis in any state that is legal medical marijuana. California goes full legal Jan 1, that state alone could yield 100s of millions in sales based on cosmetics alone and then add pain relief and skin care BILLIONS in revenue potential here with $OMHE Second it sounds like they are going after European market as well where rules are much more defined then here in USA and path to consumer much friendly to navigate. $OMHE is golden can't wait for clear guidance from our CEO bkueskies ahead BLUE SKY BREAKOUT COMETH
THINK ABOUT IT there is a reason why this stayed above .01 foe the most part there's a reason why the float is so tightly held.. find me another share structure like this with historical daily volume never exceeding 12m watch wjat happens when we get volume over 20m in a day if you own enough shares you might actually be able to stop working
$OMHE calculated moves being done in silence BIOTECH TAKES TIME or should I say REAL BIOTECH TAKES TIME ... we are GOING TO DA MOOOON!!!!!!!!!!!!!!!!!!!!!!!!!!! $OMHE HAVE A BLESSED WEEKEND BOYS AND BUBS
Welcome Carlitos Way to DOLLARLAND $OMHE is it Monday yet?
$OMHE Letter CEO to Shareholders
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
Exactly why this next update is going to be HUGE it's going to be completely unexpected the magnitude of the announcement and will immediately over night increase the value of $OMHE exponentially
$OMHE Letter from CEO to Shareholders
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
$OMHE Letter from CEO to Shareholders
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
love me $AMFE also big on $OWCP and of course $OMHE rest of the monies goes to Bitcoins
churn and burn higher highs higher lows $OMHE stairway to pennies fromm heaven
love $INNV check out $OMHE
$OMHE Letter from CEO to Shareholders
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
$OMHE Letter from CEO to Shareholders
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
I like that they are from Denmark, I will add to my watch list thank you.. $OMHE recently went current which is why I bought in here their recent share holder letter released Nov 12th
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
my broker wont let me buy stop signs when do they expect to go current?
$OMHE <.03 load it up
Patience the stock market is the transfer of wealth from impatient investors to the patient ones .. stay convicted know what you own here do your own DD do your own research and come to the conclusions many of us here have on the company .. $OWCP God Speed and God Bless have a great weekend all
Funny your claims don't match up with historical prices and dates
Next leg coming right up $OMHE
going to be a rocket launch moon shot over .03 #cantwait God Bless God Speed $OMHE
gotta think a close over .50 is in the cards today back 2 back inside inside days $OWCP gonna move here stay blessed
.024 is 420 backwards $OMHE
doubtful higher lows are being put in from here on out best of luck $OMHE
funny cause even in the last year of SILENCE the lowest $OMHE got was around .009 and that happened to be just a few days prior to our MOST RECENT UPDATE that clearly stated the lack of communication and silence due to large projects being negotiated and those coming to fruition soon SO I disagree and disregard your opinion TOODLES
$OMHE still trending up, this is healthy trading higher highs higher lows previous resistances acting as supports TOODLES
$OMHE is trending up!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!![color]
Can't wait for the official Press Release from $OMHE ANDREY PLEASE HELP ME PAY FOR CHRISTMAS !!!!!